• Formycon launched a collaboration with Biocelys to develop biosimilar candidate FYB286, combining development expertise with manufacturing capabilities.
• Santo Biosimilar will provide upfront financing; Formycon will receive arm's-length development fees and a low double-digit percentage share of Santo's future revenues.
• ATHOS, Formycon's largest anchor shareholder, indirectly controls both Santo Biosimilar and Biocelys.
• FYB286 expands the biosimilar pipeline into a niche indication; the partnership strengthens manufacturing supply capabilities beyond this project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2418978_en) on October 21, 2026, and is solely responsible for the information contained therein.